These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 9144102)

  • 41. Clinical utility of the functional independence measure for assessment of patients with Alzheimer's disease and vascular dementia.
    Tanaka N; Nakatsuka M; Ishii H; Nakayama R; Hosaka R; Meguro K
    Psychogeriatrics; 2013 Dec; 13(4):199-205. PubMed ID: 24289460
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Validation of a cognitive test for delirium in medical ICU patients.
    Hart RP; Levenson JL; Sessler CN; Best AM; Schwartz SM; Rutherford LE
    Psychosomatics; 1996; 37(6):533-46. PubMed ID: 8942204
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Paradoxical effect of methylphenidate in the treatment of a patient with severe traumatic brain injury].
    Grønborg P; Liljegren J; Jansen J
    Ugeskr Laeger; 2009 Jun; 171(26):2201-2. PubMed ID: 19671403
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacological treatment of cognitive deficits in nondementing mental health disorders
.
    Robbins TW
    Dialogues Clin Neurosci; 2019 Sep; 21(3):301-308. PubMed ID: 31749654
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neurocognitive performance and behavioral symptoms in patients with attention-deficit/hyperactivity disorder during twenty-four months of treatment with methylphenidate.
    Wang LJ; Chen CK; Huang YS
    J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):246-53. PubMed ID: 25574708
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Methylphenidate in terminal depression.
    Macleod AD
    J Pain Symptom Manage; 1998 Sep; 16(3):193-8. PubMed ID: 9769622
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of dementia rating scales in Parkinson's disease dementia.
    Harvey PD; Ferris SH; Cummings JL; Wesnes KA; Hsu C; Lane RM; Tekin S
    Am J Alzheimers Dis Other Demen; 2010 Mar; 25(2):142-8. PubMed ID: 19359706
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge.
    Herrmann N; Rothenburg LS; Black SE; Ryan M; Liu BA; Busto UE; Lanctôt KL
    J Clin Psychopharmacol; 2008 Jun; 28(3):296-301. PubMed ID: 18480686
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cognitive impairments in different stages of Parkinson's disease.
    Starkstein SE; Bolduc PL; Preziosi TJ; Robinson RG
    J Neuropsychiatry Clin Neurosci; 1989; 1(3):243-8. PubMed ID: 2521068
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of TENS and methylphenidate in tuberculous meningo-encephalitis.
    Scherder EJ; Van Deursen S; Van Manen SR; Ferenschild K; Simis R; Vuyk PJ
    Brain Inj; 2001 Jun; 15(6):545-58. PubMed ID: 11394974
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Informant-rated cognitive symptoms in normal aging, mild cognitive impairment, and dementia. Initial development of an informant-rated screen (Brief Cognitive Scale) for mild cognitive impairment and dementia.
    Krishnan KR; Levy RM; Wagner HR; Chen G; Gersing K; Doraiswamy PM
    Psychopharmacol Bull; 2001; 35(3):79-88. PubMed ID: 12397880
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neuropsychological profiles in MCI and in depression: Differential cognitive dysfunction patterns or similar final common pathway disorder?
    Zihl J; Reppermund S; Thum S; Unger K
    J Psychiatr Res; 2010 Jul; 44(10):647-54. PubMed ID: 20060127
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Syndromic validity of apathy in Alzheimer's disease.
    Starkstein SE; Petracca G; Chemerinski E; Kremer J
    Am J Psychiatry; 2001 Jun; 158(6):872-7. PubMed ID: 11384893
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Antidepressive effect of pyridoxine (vitamin B6) in neuroleptic-treated schizophrenic patients with co-morbid minor depression--preliminary open-label trial].
    Shiloh R; Weizman A; Weizer N; Dorfman-Etrog P; Munitz H
    Harefuah; 2001 May; 140(5):369-73, 456. PubMed ID: 11419053
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Difficulties in the evaluation of depressive symptoms in patients with dementia].
    Schneider B; Weber B; Maurer K; Frölich L
    Psychiatr Prax; 2002 Mar; 29(2):76-82. PubMed ID: 11894187
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].
    Robert PH; Schuck S; Dubois B; Lépine JP; Gallarda T; Olié JP; Goni S; Troy S
    Encephale; 2003; 29(3 Pt 1):266-72. PubMed ID: 12876552
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Methylphenidate Treatment for Patients With Posterior Cortical Atrophy.
    Mendez MF
    J Neuropsychiatry Clin Neurosci; 2018; 30(4):334-336. PubMed ID: 29685063
    [No Abstract]   [Full Text] [Related]  

  • 58. Methylphenidate for depression in the elderly, medically ill patient.
    Frye CB
    Am J Health Syst Pharm; 1997 Nov; 54(21):2510-1. PubMed ID: 9359961
    [No Abstract]   [Full Text] [Related]  

  • 59. Use of methylphenidate in patients with cancer.
    Sood A; Barton DL; Loprinzi CL
    Am J Hosp Palliat Care; 2006; 23(1):35-40. PubMed ID: 16450661
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Methylphenidate in a patient with depression and respiratory insufficiency.
    Ayache DC; Junior RF
    Int J Psychiatry Med; 2001; 31(4):443-9. PubMed ID: 11949742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.